Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Welcome and Introduction to Vi3C

Varsha Gandhi, PhD, on Ibrutinib

Dec

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Welcome and Introduction to Vi3C

Varsha Gandhi, PhD, on Ibrutinib

Large AI Breast Cancer Screening Trial Increases Detection Rate

P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti-PD-1 Therapy in Early Breast Cancer

Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer

Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy-Refractory Advanced Breast Cancers

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers